GENMAB AS DK 1/ DK0010272202 /
2024-04-25 10:59:45 PM | Chg. -8.10 | Volume | Bid10:59:45 PM | Ask10:59:45 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
256.30EUR | -3.06% | - Turnover: - |
256.30Bid Size: - | 258.60Ask Size: - | 16.97 bill.EUR | - | - |
GlobeNewswire
04-03
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
2023-10-17
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
2023-09-25
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
2023-09-04
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
2021-10-19
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
2021-09-20
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
2021-07-21
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
GlobeNewswire
2021-06-22
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumu...
GlobeNewswire
2021-05-21
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab...
GlobeNewswire
2021-04-20
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021